Insider · CIK 0001824632

Scherle Peggy

Reports to the SEC for 1 company · WILMINGTON, DE

sec.gov

Transactions

Companies

Filings

CIK

0001824632

Forms 4 and 5

Insider transactions

39 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-04	PRLDPrelude Therapeutics Inc · Employee Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+230K sh	—	—	230,000
2025-02-04	PRLDPrelude Therapeutics Inc · Employee Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+175K sh	—	—	175,000
2024-03-01	PRLDPrelude Therapeutics Inc · Employee Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+150K sh	—	—	150,000
2023-02-07	PRLDPrelude Therapeutics Inc · Employee Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+135K sh	—	—	135,000
2022-02-15	PRLDPrelude Therapeutics Inc · Employee Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+100K sh	—	—	100,000
2021-08-27	PRLDPrelude Therapeutics IncM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+6,014 sh	$1.43	+$8,600.02	178,934
2021-08-27	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−2,700 sh	$35.32	−$95.4K	176,234
2021-08-27	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−2,707 sh	$36.23	−$98.1K	173,527
2021-08-27	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−607 sh	$37.08	−$22.5K	172,920
2021-08-27	PRLDPrelude Therapeutics Inc · Employee Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−6,014 sh	—	—	27,018
2021-08-26	PRLDPrelude Therapeutics IncM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+1,700 sh	$1.43	+$2,431	174,620
2021-08-26	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−1,700 sh	$35.19	−$59.8K	172,920
2021-08-26	PRLDPrelude Therapeutics Inc · Employee Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−1,700 sh	—	—	33,032
2021-08-13	PRLDPrelude Therapeutics IncM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+558 sh	$1.89	+$1,054.62	173,478
2021-08-13	PRLDPrelude Therapeutics IncM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+1,728 sh	$1.43	+$2,471.04	175,206
2021-08-13	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−2,286 sh	$35.07	−$80.2K	172,920
2021-08-13	PRLDPrelude Therapeutics Inc · Employee Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−558 sh	—	—	42,672
2021-08-13	PRLDPrelude Therapeutics Inc · Employee Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−1,728 sh	—	—	34,732
2021-07-27	PRLDPrelude Therapeutics IncM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+20K sh	$1.43	+$28.6K	192,920
2021-07-27	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−19.3K sh	$35.45	−$685K	173,600
2021-07-27	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−680 sh	$36.09	−$24.5K	172,920
2021-07-27	PRLDPrelude Therapeutics Inc · Employee Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−20K sh	—	—	36,460
2021-07-20	PRLDPrelude Therapeutics Inc · Employee Stock Option (Right to Buy)A Award	Chief Scientific Officer	AAward	+95K sh	—	—	95,000
2021-05-07	PRLDPrelude Therapeutics IncM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+10K sh	$1.43	+$14.3K	182,920
2021-05-07	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−3,964 sh	$40.30	−$160K	178,956
2021-05-07	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−5,836 sh	$41.14	−$240K	173,120
2021-05-07	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−200 sh	$41.85	−$8,370	172,920
2021-05-07	PRLDPrelude Therapeutics Inc · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−10K sh	—	—	56,460
2021-04-08	PRLDPrelude Therapeutics IncA Award	Chief Scientific Officer	AAward	+4,630 sh	$1.43	+$6,620.9	177,550
2021-04-08	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−1,417 sh	$36.97	−$52.4K	176,133
2021-04-08	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−875 sh	$37.72	−$33K	175,258
2021-04-08	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−669 sh	$38.97	−$26.1K	174,589
2021-04-08	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−1,669 sh	$39.57	−$66K	172,920
2021-04-08	PRLDPrelude Therapeutics Inc · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−4,630 sh	—	—	66,460
2021-04-07	PRLDPrelude Therapeutics IncA Award	Chief Scientific Officer	AAward	+15.4K sh	$1.43	+$22K	188,290
2021-04-07	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−8,289 sh	$39.02	−$323K	180,001
2021-04-07	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−6,881 sh	$39.63	−$273K	173,120
2021-04-07	PRLDPrelude Therapeutics IncS Sale	Chief Scientific Officer	SSale	−200 sh	$40.30	−$8,060	172,920
2021-04-07	PRLDPrelude Therapeutics Inc · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−15.4K sh	—	—	71,090

Recent filings

Accepted (ET)
Feb 54
Scherle Peggy0001824632-26-000002
SEC(opens sec.gov)
Feb 54
Scherle Peggy0001562180-25-000958
SEC(opens sec.gov)
Mar 44
Scherle Peggy0001562180-24-002137
SEC(opens sec.gov)
Feb 94
Scherle Peggy0001562180-23-001170
SEC(opens sec.gov)
Feb 174
Scherle Peggy0001209191-22-011038
SEC(opens sec.gov)
Aug 304
Scherle Peggy0001209191-21-053867
SEC(opens sec.gov)
Aug 174
Scherle Peggy0001209191-21-051885
SEC(opens sec.gov)
Jul 294
Scherle Peggy0001209191-21-048688
SEC(opens sec.gov)

Companies

Prelude Therapeutics IncChief Scientific OfficerPRLD

Address

C/O PRELUDE THERAPEUTICS INCORPORATED 175 INNOVATION BOULEVARD

WILMINGTON, DE, 19805